Abstract
Despite the recent advances in parallel protein-based analyses the proportion of the protein composition of any specific tissue or organism that is currently being analyzed is still unknown. The ultimate aim of proteomics is to characterize all of the proteins in a biological system under study, but much has been gained from knowledge of smaller subsets of the proteome. Therefore, while techniques and instrumentation are being improved to increase the sensitivity of analysis, it is just as important to answer the question of what depth of analysis is required for reasonable conclusions to be reached. The questions to be answered and the resulting depth of analysis required will vary depending upon whether the understanding is required for diagnostic markers, therapeutic targets or biological systems. The issues associated with increasing the depth of analysis of proteins in the context of these areas will be discussed. However, it should be noted that merely increasing the amount of data acquired will not necessarily increase the amount of knowledge of a particular system and as such careful implementation of proteomic methods is required to advance these fields of research.
Keywords: parallel protein analysis, mass spectrometry, proteome, proteomics
Current Proteomics
Title: How Much of the Proteome Do We See with Discovery-Based Proteomics Methods and How Much Do We Need to See?
Volume: 1 Issue: 1
Author(s): Scott D. Patterson
Affiliation:
Keywords: parallel protein analysis, mass spectrometry, proteome, proteomics
Abstract: Despite the recent advances in parallel protein-based analyses the proportion of the protein composition of any specific tissue or organism that is currently being analyzed is still unknown. The ultimate aim of proteomics is to characterize all of the proteins in a biological system under study, but much has been gained from knowledge of smaller subsets of the proteome. Therefore, while techniques and instrumentation are being improved to increase the sensitivity of analysis, it is just as important to answer the question of what depth of analysis is required for reasonable conclusions to be reached. The questions to be answered and the resulting depth of analysis required will vary depending upon whether the understanding is required for diagnostic markers, therapeutic targets or biological systems. The issues associated with increasing the depth of analysis of proteins in the context of these areas will be discussed. However, it should be noted that merely increasing the amount of data acquired will not necessarily increase the amount of knowledge of a particular system and as such careful implementation of proteomic methods is required to advance these fields of research.
Export Options
About this article
Cite this article as:
Patterson D. Scott, How Much of the Proteome Do We See with Discovery-Based Proteomics Methods and How Much Do We Need to See?, Current Proteomics 2004; 1 (1) . https://dx.doi.org/10.2174/1570164043488306
DOI https://dx.doi.org/10.2174/1570164043488306 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Irreversible Multitargeted ErbB Family Inhibitors for Therapy of Lung and Breast Cancer
Current Cancer Drug Targets Dietary Fatty Acids in Metabolic Syndrome, Diabetes and Cardiovascular Diseases
Current Diabetes Reviews Action of Nanoparticles on Platelet Activation and Plasmatic Coagulation
Current Medicinal Chemistry Biological Therapies For Inflammatory Bowel Disease: Research DrivesClinics
Mini-Reviews in Medicinal Chemistry Effects of Antiretroviral Therapy on Immunity in Patients Infected with HIV
Current Pharmaceutical Design 2-Aminoimidazole, Glycociamidine and 2-Thiohydantoin-Marine Alkaloids as Molecular Inspirations for the Development of Lead Structures
Current Drug Targets Hypoxia Signaling and the Metastatic Phenotype
Current Molecular Medicine Optimization of Lentiviral Vectors Generation for Biomedical and Clinical Research Purposes: Contemporary Trends in Technology Development and Applications
Current Gene Therapy Apoptosis Induction by Erucylphosphohomocholine via the 18 kDa Mitochondrial Translocator Protein: Implications for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Cullin-RING Ligases as Attractive Anti-cancer Targets
Current Pharmaceutical Design Targeting Angiogenesis in Renal Cell Carcinoma
Current Cancer Drug Targets Therapeutic Potential of Janus Kinase 3 (JAK3) Inhibitors
Current Pharmaceutical Design Recent Advances in Superparamagnetic Iron Oxide Nanoparticles for Cellular Imaging and Targeted Therapy Research
Current Pharmaceutical Design From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design Epigenetic Modifications as Therapeutic Targets
Current Drug Targets Colon Targeted Liposomal Systems (CTLS): Theranostic Potential
Current Molecular Medicine Gene Electrotransfer to Skin; Review of Existing Literature and Clinical Perspectives
Current Gene Therapy Extracellular Vesicles as Innovative Tools for Assessing Adverse Effects of Immunosuppressant Drugs
Current Medicinal Chemistry Endostatin: Preclinical Development as an Anticancer Agent
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Small Molecule Inhibitors of Stat3 Signaling Pathway
Current Cancer Drug Targets